Amgen Inc. is a biotechnology company founded in 1980 as Applied Molecular Genetics. In FY2025, Amgen reported $36.8 billion in total revenues, $7.7 billion in net income, and approximately 31,500 staff members.
Amgen Key Facts
- Founded in 1980 by George B. Rathmann and William K. Bowes Jr.
- Headquarters: Thousand Oaks, California.
- CEO: Robert A. Bradway.
- Nasdaq ticker: AMGN.
- FY2025 revenue: $36.8 billion.
- FY2025 net income: $7.7 billion.
- FY2025 staff: approximately 31,500.
How Amgen Makes Money
Amgen earns revenue by discovering, developing, manufacturing, and commercializing biologic medicines, small molecules, biosimilars, and rare disease therapies. Its portfolio includes established products in inflammation, oncology, bone health, cardiovascular disease, and rare disease, alongside pipeline programs that determine long-term growth.
FY2025 Strategic Context
Amgen's FY2025 results reflect the scale of its legacy biologics franchise, the contribution from Horizon Therapeutics products, biosimilar expansion, and investment in newer pipeline opportunities. The company competes with large pharmaceutical groups and focused biotechnology peers, where clinical data, manufacturing scale, patent life, and reimbursement access all matter.
Current Risks
The main risks are patent expirations, drug pricing pressure, clinical trial uncertainty, biosimilar competition, and the execution required to convert pipeline assets into durable revenue.
